We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
- Authors
Cohen, Ezra E W; Rosen, Lee S; Vokes, Everett E; Kies, Merrill S; Forastiere, Arlene A; Worden, Francis P; Kane, Madeleine A; Sherman, Eric; Kim, Sinil; Bycott, Paul; Tortorici, Michael; Shalinsky, David R; Liau, Katherine F; Cohen, Roger B
- Abstract
Patients with advanced, incurable thyroid cancer not amenable to surgery or radioactive iodine ((131)I) therapy have few satisfactory therapeutic options. This multi-institutional study assessed the activity and safety of axitinib, an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 in patients with advanced thyroid cancer.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 29, p4708
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.15.9566